RESUMO
OBJECTIVE: To evaluate the therapeutic efficacy of deoxyribonucleotidum in treatment of acute viral myocarditis. METHODS: Eighty-eight patients with acute viral myocarditis were randomized equally into therapeutic group and control group. Patients in the control group were treated with routine treatment and those in the therapeutic group were given deoxyribonucleotidum in addition to routine treatment. After 4 weeks, the total efficacy rate and median time of symptom disappearance were compared between the two groups. RESULTS: The total efficacy rate in the control and therapeutic groups was 79.54% and 95.45% (P=0.049), and the median time of symptom disappearance was 9.5 days and 6.5 days, respectively (P=0.035). Hypotension and mild dizziness were found in 2 patients in the therapeutic group without other severe side effects. CONCLUSION: Deoxyribonucleotidum can improve the therapeutic effect for acute viral myocarditis.
Assuntos
Desoxirribonucleotídeos/uso terapêutico , Miocardite/tratamento farmacológico , Viroses/tratamento farmacológico , Adolescente , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do TratamentoRESUMO
OBJECTIVE: To evaluate of therapeutic efficacy of deoxyribouncleotidum on pulmonary tuberculosis. METHODS: Eighty patients with pulmonary tuberculosis sustaining hepatic lesion after treatment with antituberculosis drugs were randomized into therapeutic group and control group. Patients in the control group received regular treatment and those in the therapeutic group had additional deoxyribouncleotidum injection. RESULTS: ALT, AST, ALP and TBIL levels were significantly higher in the therapeutic group than in the control group 4 weeks after treatment. IgG, IgA, IgM levels, and CD3(+) and CD8(+) lymphocytes were significantly increased in the therapeutic group after treatment (P<0.05). CONCLUSION: deoxyribouncleotidum can improve hepatic function and immunity in patients with pulmonary tuberculosis.
Assuntos
Desoxirribonucleotídeos/uso terapêutico , Hepatopatias/tratamento farmacológico , Tuberculose Pulmonar/tratamento farmacológico , Adjuvantes Imunológicos/administração & dosagem , Adjuvantes Imunológicos/uso terapêutico , Adulto , Alanina Transaminase/metabolismo , Antituberculosos/efeitos adversos , Antituberculosos/uso terapêutico , Aspartato Aminotransferases/metabolismo , Complexo CD3/imunologia , Linfócitos T CD8-Positivos/citologia , Linfócitos T CD8-Positivos/efeitos dos fármacos , Linfócitos T CD8-Positivos/imunologia , Doença Hepática Induzida por Substâncias e Drogas , Desoxirribonucleotídeos/administração & dosagem , Feminino , Humanos , Imunoglobulina A/sangue , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Injeções , Hepatopatias/sangue , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento , Tuberculose Pulmonar/sangueAssuntos
DNA Antissenso/síntese química , Desoxirribonucleotídeos/química , Leucemia Mieloide Aguda/tratamento farmacológico , Tionucleotídeos/síntese química , Ensaios Clínicos Fase I como Assunto , DNA Antissenso/genética , DNA Antissenso/uso terapêutico , Desoxirribonucleotídeos/genética , Desoxirribonucleotídeos/uso terapêutico , Regulação da Expressão Gênica , Genes p53 , Humanos , Tionucleotídeos/genética , Tionucleotídeos/uso terapêuticoRESUMO
A DNA sequencing system based on the use of a novel set of four chain-terminating dideoxynucleotides, each carrying a different chemically tuned succinylfluorescein dye distinguished by its fluorescent emission is described. Avian myeloblastosis virus reverse transcriptase is used in a modified dideoxy DNA sequencing protocol to produce a complete set of fluorescence-tagged fragments in one reaction mixture. These DNA fragments are resolved by polyacrylamide gel electrophoresis in one sequencing lane and are identified by a fluorescence detection system specifically matched to the emission characteristics of this dye set. A scanning system allows multiple samples to be run simultaneously and computer-based automatic base sequence identifications to be made. The sequence analysis of M13 phage DNA made with this system is described.
Assuntos
Sequência de Bases , DNA/genética , Desoxirribonucleotídeos , Corantes Fluorescentes , Automação , Vírus da Mieloblastose Aviária/enzimologia , Bacteriófagos/genética , DNA Viral/genética , Desoxirribonucleotídeos/efeitos adversos , Desoxirribonucleotídeos/uso terapêutico , Eletroforese em Gel de Poliacrilamida , Fluoresceínas , DNA Polimerase Dirigida por RNA/metabolismo , Espectrometria de Fluorescência , SuccinatosRESUMO
The triple combination of 2'-deoxycoformycin (2'-dCF), 9-beta-D-arabinofuranosyladenine 5'-phosphate, and 9-beta-D-arabinofuranosylcytosine was found to be very effective in the therapy of C57BL X DBA/2 F1 mice with intracerebral L1210. At the dosages and dosage scheduling used, the double combination of 2'-dCF and 9-beta-D-arabinofuranosyladenine 5'-phosphate gave minimal but significant increases in life-span. When 9-beta-D-arabinofuranosylcytosine was given at suboptimal dosage to mice with intracerebral L1210, the host toxicity caused by 2'-dCF and 9-beta-D-arabinofuranosyladenine 5'-phosphate in combination was decreased by a factor of 2, allowing a more prolonged therapy. "Cures" were obtained with the triple combination at dosages of 9-beta-D-arabinofuranosylcytosine that did not "cure". The supernatant adenosine deaminase from C57BL X DBA/2 F1 mouse brains was purified and the Ki for 2'-dCF using 9-beta-D-arabinofuranosyladenine as substrate was determined to be not more than 2 X 10(-11) M.